PMID: 9542321May 16, 1998Paper

Treatment of elderly patients with AML: results of an individualized approach

Haematologica
J C Hernández-BoludaE Montserrat

Abstract

AML treatment in elderly patients must be individualized according to their characteristics. We report the results of a tailored treatment approach in all consecutive AML patients older than 60 years diagnosed at our institution during the last 2 years. Between December 1994 and December 1996, 43 AML patients over 60 years of age (median, 72; range 61-89) were managed according to their performance status (PS) and associated diseases. Twenty patients (46%) were eligible for intensive chemotherapy and received combination chemotherapy including an anthracycline (Idarubicin or daunorubicin), ara-C and VP-16. After complete remission (CR), consolidation chemotherapy with mitoxantrone and intermediate-high-dose ara-C was given to 13 of the 15 patients in remission (65% of all patients candidates for intensive treatment). Twenty-three patients who were not eligible for intensive chemotherapy received palliative measures. Patients treated with one course of intensive chemotherapy had a CR rate of 70% (95% CI: 48-92%)(n = 14) with a mortality rate of 20% (n = 4) and a resistance of 10% (n = 2). An additional patient reached CR after rescue therapy. Median CR duration was 10.5 months. Median survival was 10.5 months. Patients above 70 ...Continue Reading

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Breast Cancer : the Journal of the Japanese Breast Cancer Society
Hideo Inaji, Futoshi Akiyama
Journal of Clinical Orthodontics : JCO
Robert G Keim
British Journal of Haematology
Chris Bunce
© 2022 Meta ULC. All rights reserved